Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

However, the overall safety profile of taspoglutide was clearly worse than exenatide with respect to gastrointestinal tolerability, systemic allergic reactions, and injection-site reactions.

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

In this case report, Gad and colleagues performed corneal confocal microscopy to assess for evidence of nerve regeneration ...

Semaglutide, the weight management drug sold as Ozempic and Wegovy, may reduce the risk of Alzheimer's disease by 40% to 70% compared to similar medications, a new study found. But experts say more ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

They were older GLP-1s: albiglutide, dulaglutide, exenatide, liraglutide, and lixisenatide. Semaglutide was also linked to significantly lower Alzheimer's-related medication prescriptions.

exenatide, liraglutide, and lixisenatide). Their methodology involved using target trial emulation, a type of study that aims to mimic a randomized controlled trial (RCT) but uses existing data ...